Euro
USD
British Pound
NULL
Product Description
Tremelimumab (CTLA4/CD152) Antibody, Monoclonal | 10-266 | ProSci
Host: N/A
Reactivity: N/A
Homology: N/A
Immunogen: Homo sapiens / CTLA4/CD152 [Homo sapiens]
Research Area: Drug Analogues
Tested Application: N/A
Application: N/A
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: >95%
Clonality: Monoclonal
Clone: N/A
Isotype: IgG2-kappa
Conjugate: Unconjugated
Physical State: N/A
Buffer: PBS buffer pH7.5
Concentration: N/A
Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.
Alternate Name: CP-675, CP-675, 206, CP-675206 clone 11.2.1
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: Tremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part A and B: Advanced Solid Malignancies.
